Atamyo Therapeutics Announces First Patient Dosed with ATA-100 Gene Therapy in LGMD-R9 Clinical Trial

First patient dosed with ATA-100 gene replacement therapy for LGMD-R9 On-going multicenter, Phase 1/2 study evaluating safety, pharmacodynamic and efficacy of ATA-100 Atamyo Therapeutics

Related Keywords

United States ,Paris ,France General ,France ,Copenhagen ,Køavn ,Denmark ,United Kingdom ,Greece ,Greek ,Kostenloser Wertpapierhandel ,Stephane Degove ,John Vissing ,Charles Craig ,Sophie Olivier ,Isabelle Richard ,Copenhagen Neuromuscular Center ,Progressive Muscular Dystrophies Laboratory At Genethon ,Drug Administration ,European Medicines Agency ,Opus Biotech Communications ,National Hospital ,Chief Executive Officer ,Adeno Associated Virus ,Chief Medical Officer ,Progressive Muscular Dystrophies Laboratory ,Orphan Drug Designation ,European Medicines ,Celtic Atao ,Atamyo ,Herapeutics ,Nnounces ,First ,Patient ,Hosed ,Gene ,Therapy ,Sgmd ,Linical ,Trial ,